Ruxolitinib
Hematopoietic And Lymphoid System Neoplasm
Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Stanford University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05088356CT.gov Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | — | Active Not Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04016116CT.gov Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ruxolitinib (this asset) | Stanford University | P2 | B · 59 |
| Adriamycin | OHSU Knight Cancer Institute | P4 | BBB |
| Teclistamab | Janssen Pharmaceutical K.K. | P2 | BB |
| Dexasone | City of Hope Medical Center | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf) | Gamida Cell ltd | P3 | BB |
| Bortezomib | OHSU Knight Cancer Institute | P4 | BB |
| Etoposide | Ciusss de L'Est de l'Île de Montréal | P2 | BB |
| Pembrolizumab | Vividion Therapeutics, Inc. | P3 | BB |
+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort
Other indications for Ruxolitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Myelofibrosis | — | P4 | BBB · 73 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BB · 70 |
| Graft Versus Host Disease | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinOHSU Knight Cancer InstituteBBB
- TeclistamabJanssen Pharmaceutical K.K.BB
- DexasoneCity of Hope Medical CenterBB
- CyclophosphamideNational Cancer Institute (NCI)BB
- Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdBB
Citation
Floatz Terminal. Ruxolitinib in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ruxolitinib-hematopoietic-and-lymphoid-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →